Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population

Abstract

Direct oral anticoagulants (DOACs) have led to a paradigm shift in the field of anticoagulation, providing safe and convenient anticoagulation without the need for regular blood testing. Currently, there are three major DOACs available—Factor Xa inhibitors (apixaban and rivaroxaban) and direct thrombin inhibitors (dabigatran)—that are available for use in atrial fibrillation and venous thromboembolism. While these agents have been shown to be as effective as warfarin, with a similar or better bleeding profile, there remains some concern of the use of these drugs in vulnerable populations, such as the frail elderly patients; particularly since reversal agents and drug monitoring are not routinely available. We aim to provide a review of the use of DOACs and the impact of DOACs on dental treatment in the elderly population.

Keywords

• direct oral anticoagulants
• factor Xa inhibitor
• direct thrombin inhibitor
• bleeding
• frail elderly